The study of absorbable sustained-release implants and animal experiments to prevent recurrence of bladder cancer.
- Author:
Meili YU
1
;
Zhi DU
;
Junchen XUE
;
Keming WANG
Author Information
1. Tianjin Third Central Hospital, Tianjin Key Laboratory of Artificial Cells, Tianjin 300170, China. yumeili8@163.com
- Publication Type:Journal Article
- MeSH:
Absorbable Implants;
Animals;
Antineoplastic Agents;
administration & dosage;
Chromatography, High Pressure Liquid;
methods;
Delayed-Action Preparations;
administration & dosage;
chemistry;
Doxorubicin;
administration & dosage;
analogs & derivatives;
Female;
Implants, Experimental;
Male;
Neoplasm Recurrence, Local;
prevention & control;
Polyanhydrides;
administration & dosage;
chemistry;
Postoperative Period;
Rabbits;
Random Allocation;
Urinary Bladder Neoplasms;
drug therapy;
surgery
- From:
Journal of Biomedical Engineering
2011;28(2):322-325
- CountryChina
- Language:Chinese
-
Abstract:
This paper aims to prepare polyanhydride-Pirarubicin dose long-acting sustained-release implants for the treatment of bladder cancer and for the prevention of postoperative recurrence of bladder cancer. Pirarubicin hydrochloride (THP) and polyanhydride, in accordance with a certain proportion, were fully mixed in the agate morta and dissolved in dichloromethane, and then were cast into a film within a mold put in the dryer set at 4 degrees C. Each tablet implanted contained 5.0 mg of THP. Polyanhydride-pirarubicin sustained-release was implanted into the bladder mucosa of the rabbits, and blood and urine samples were taken at different times after the operation. The THP drug concentrations in urine and blood were determined with high-performance liquid chromatography. The THP concentration in urine was significantly higher than the THP concentration in plasma. The drug concentration in urine reached (92.5 +/- 7.4) microg/L at 250 d time after the operation. Polyanhydride-pirarubicin implants possess long-acting sustained-release level dynamics in the body. It can maintain a stable long-term drug release and can be expected to last a year and can effectively prevent recurrence of bladder cancer. The present experiments proved that the implants with sustained-release drug treatment are expected to be useful in the clinical application in prevention of bladder cancer recurrence.
